(Photo by Flickr user Luca Volpi, used under a Creative Commons license)
Personal Genome Diagnostics (PGDx) received a new contract from the U.S. Department of Veterans Affairs to provide a test for cancer that does not require tissue samples.
The Canton-based company makes a liquid biopsy, which tests for cancer by evaluating 64 genes that are associated with cancer.
The test can be conducted through a blood test, rather than obtaining tissue samples through a traditional biopsy or conducting an ultrasound. The test can also be conducted multiple times during treatment, providing a “real-time livestream of what’s happening at the genetic level in the patient’s tumor or tumors,” PGDx Manager for Translational Science and Diagnostics John Simmons told Technical.ly last year.
The test will be offered to advanced cancer patients who are receiving treatment in the VA, according to the company.
The company’s work on liquid biopsy got attention from the White House last year, when Vice President Joe Biden included PGDx among the group of experts working on the Cancer Moonshot.
The new contract is an expansion of work with the VA for PGDx, which was founded by Johns Hopkins researchers. PGDx also has a contract to provide its product which analyzes tumors on the genetic level.
The company raised a $21.4 million Series A in 2015.-30-
Fearless joins coalition of agile federal government-facing tech firms
This JHU team is developing tools to assess newborn health
Medical education startup Osmosis raises $4M Series A
Building a data acquisition system? Don’t make this mistake
Why LifeBridge Health and CareFirst are collaborating on startup engagement
Baltimore’s Sonavi Labs takes third place at Startup World Cup
Find education and internship opps at Maryland’s federal agencies in this database
How SmartLogic accelerated these startups’ product growth trajectories
Sign-up for daily news updates from Technical.ly Baltimore